Floatz logo

Ibrutinib

Richter Transformation

City of Hope Medical CenterSmall moleculePhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
81/ 100

Competitive context

56 Active assets in the Richter Transformation cohort.

Asset / SponsorPhaseRating
Obinutuzumab
Christine Ryan
Phase 2BB
Venetoclax
Northwestern University
Phase 2BB
Pirtobrutinib
SWOG Cancer Research Network
Phase 3BB
Cyclophosphamide
SWOG Cancer Research Network
Phase 3BB
Humax-Cd20
University of Oxford
Phase 2BB

View all 50 →

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaActive
BBB
Indicative · Phase 4
72 / 100
View asset →
Waldenstrom macroglobulinemiaActive
BB
Indicative · Phase 4
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →